MolecuLight *i:X* Wound Imaging Device

Incorporating the MolecuLight i:X into standard care helps clinicians measure wounds^{1,2} and detect fluorescent bacteria³⁻⁷ to facilitate evidence-based clinical decisionmaking in these areas of wound management:

ASSESSMENT

In a multisite, clinical trial, red fluorescence on MolecuLight i:X images was indicative of bacterial loads of ≥10⁴ CFU/g (moderate/heavy levels) 100% of the time.⁴ This real-time information, used in conjunction with clinical signs and symptoms, may assist a clinician in their wound assessment and treatment plan.

DEBRIDEMENT

In clinical studies and case series, the MolecuLight *i*:X has been shown to demonstrate the need for debridement, identify the extent of debridement required, and facilitate targeted debridement to areas where fluorescent bacteria are located.3,6,9

DOCUMENTATION

Provides objective documentation of the presence of fluorescent bacteria³⁻⁷ and the surface area of the wound.1,2

ANTIMICROBIAL STEWARDSHIP

In case series, real-time fluorescence images prevented potentially unnecessary use of systemic and topical antibiotics in wound patients⁶ and identified asymptomatic wound patients with heavy bacterial burden, prompting antibiotic prescription.6,14

CLEANING

In case series, the MolecuLight *i*:X has been shown to direct clinician focus for cleaning to areas where fluorescent bacteria are located,^{6,8} thereby optimizing wound bed preparation.8

SAMPLING

Guides where to sample;^{4-6,10} in a clinical trial, fluorescence targeted sampling was more accurate than standard practice in detecting the presence of moderate to heavy bacterial loads.⁵ A meta-analysis reported an average fluorescence-guided sampling accuracy of 86%.1

TREATMENT SELECTION

In a case series, fluorescence images provided real-time, objective documentation to support skin graft procedures;11 planned grafting procedures were halted when fluorescent bacteria were visualized.11 Clinical studies have shown that fluorescent images also provide real-time objective feedback on treatment plan effectiveness.6,11-13

PATIENT ENGAGEMENT

In a clinical case study, fluorescence images facilitated patient engagement and were associated with an improvement in patient treatment plan adherence.15 Patients easily understood the bright colors on images in regions where fluorescent bacteria were present.16

MolecuLight *i:X*[™] Wound Imaging Device



References:

- Dunham D et al. Objective wound measurement software on a point-of-care, hand-held fluorescence imaging device: verification of measurement accuracy and repeatability. Presented at EWMA 2018. 1.
- Rennie MY et al. Accuracy and intra-user variability of a wound area measurement software. Presented at CAET 2017.
- DaCosta RS et al. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLOS ONE, 2015. З.
- Rennie MY et al. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. J Wound Care., 2017. Ottolino-Perry K et al. Improved detection of clinically relevant wound bacteria using autofluorescence image-guided sampling in diabetic foot ulcers. Int Wound J., 2017. 4
- 5.
- 6. Hill R et al. Using bacterial fluorescence imaging and antimicrobial stewardship to guide wound management practices: a case study. Ostomy Wound Manage., 2018
- 7. Blumenthal E et al. The use of the MolecuLight i:X in managing burns: a pilot study. J Burn Care Res., 2017. 8.
- Hill R et al. The use of the Molecularity in managing burns, a pilot study, 3 burn care res., 2017. Hill R et al. Shifting focus: implications of perivound bacterial load on wound hygiene. Presented at EWMA 2018. Raizman R. Targeting curettage debridement to regions of bioburden in diabetic foot ulcers (DFUs) with real-time bacterial fluorescence imaging. Presented at EWMA 2017. 9.
- 10. Blackshaw EL et al. Efficacy of an imaging device at identifying the presence of bacteria in wounds at a plastic surgery outpatients clinic. J Wound Care, 2018.
- 11 Jeffery, S. The utility of MolecuLight bacterial sensing in the management of burns and traumatic wounds. The proceedings of SPIE 2019. In press.
- Raizman R. Handheld real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes in inpatients undergoing negative pressure wound therapy. Presented at 12. EWMA 2017
- 13. Blumenthal E et al. Autofluorescence imaging for evaluating debridement in military and trauma wounds. Mil Med., 2018.
- Wu YC et al. Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. Int Wound J., 2016. Raizman R. Handheld real-time bacterial fluorescence imaging guides wound cleaning and facilitates patient education in pilonidal sinus wound care patients. Presented at EWMA 2017. 14.
- 15.

©2019 MolecuLight® Inc. All Rights Reserved. PN 1511 Rev 1.0

The MolecuLight *t*:X™ Imaging Device is approved by Health Canada (Medical License #95784) and has CE marking (Certificate #G1160292355002) for sale in Canada and the European Union. The MolecuLight *t*:X™ Imaging Device has received FDA De Novo clearance, please see https://us.moleculight.com/ for USA specific intended & indications for use.

MolecuLight® and Look to Heal® are Registered Trademarks in Canada, the EU, and the USA

moleculight.com